SPRY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the provided data, ARS Pharmaceuticals Inc (SPRY) is not a strong buy for a beginner, long-term investor at this moment. The technical indicators are bearish, financial performance is weak, and there are no significant positive catalysts or trading signals to support a buy decision. Holding off for now is the most prudent choice.
The technical indicators for SPRY are bearish. The MACD is negatively expanding (-0.0139), RSI is neutral at 33.366, and moving averages indicate a downward trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level (S1: 8.124), but no clear reversal signals are present.
Hedge funds are significantly increasing their positions in SPRY, with a 326% increase in buying over the last quarter.
The company's financial performance in Q4 2025 is severely weak, with revenue down 67.56% YoY, net income down 182.76% YoY, and EPS down 200% YoY. Additionally, there are no recent news catalysts or significant insider trading activity.
In Q4 2025, SPRY's financials showed significant declines: revenue dropped to $28.09M (-67.56% YoY), net income dropped to -$41.32M (-182.76% YoY), EPS dropped to -0.42 (-200% YoY), and gross margin dropped to 78.09% (-21.12% YoY).
No data on recent analyst ratings or price target changes is provided, making it difficult to gauge Wall Street sentiment.
